129207-94-9

Upstream product

• 108-56-5 diethyl oxaloacetate 
• 10495-09-7 ethyl 4,4-diethoxyacetoacetate 
• 89429-70-9 4-(2,3-Dichloro-phenyl)-2-diethoxymethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester 
• 129207-92-7 2-carboxy-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 89429-69-6 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-2-formyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 121223-46-9 4-Chloro-2-[1-(2,3-dichloro-phenyl)-meth-(Z)-ylidene]-3-oxo-butyric acid ethyl ester 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 121223-50-5 (3S,4S)-2-[1-Chloro-meth-(Z)-ylidene]-4-(2,3-dichloro-phenyl)-6-methyl-1,2,3,4-tetrahydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester 
• 98192-79-1 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-2-hydroxymethyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 

Downstream Products

• 129258-90-8 (2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-(2-pyridyl)methoxymethyl-1,4-dihydropyridine 
• 129207-95-0 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-2-(methoxycarbonyl methylthio)methyl-6-methyl-1,4-dihydropyridine 
• 109857-99-0 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-2-(2-hydroxyethylthiomethyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 129207-96-1 2-(benzylthiomethyl)-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 121223-52-7 2-Chloromethyl-4-(2,3-dichloro-phenyl)-6-methyl-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester 
• 106853-02-5 2-(2-aminoethylthiomethyl)-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 123754-02-9 4-(2,3-Dichloro-phenyl)-2-imidazol-1-ylmethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester 

Relevant academic research and scientific papers

Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines

An approach to the design of potential combined antithrombotic-antihypertensive agents is described. A series of 1,4-dihydropyridines bearing a 1H-imidazol-1-yl or pyrid-3-yl substituted side chain in the 2-position were synthesized and tested for antihypertensive activity in spontaneously hypertensive rats and for inhibition of TXA2 synthetase in rabbit platelets, in vitro. 1,4-Dihydro-2-(1H-imidazol-1-ylmethyl) -6-methyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid 3-ethyl 5-methyl diester (1) was shown to be similar in potency to nitrendipine as an antihypertensive agent. Compound 1 inhibited TXA2 synthetase in rabbit and human platelets in vitro and reduced plasma TXB2 levels in rats at antihypertensive dose levels. The reductions in thromboxane production observed in vivo and in vitro were accompanied by enhanced levels of 6-KPGF(1α), reflecting diversion of the arachidonic acid cascade toward prostacyclin synthesis.

Ca(2+)-MODULATORS. UNUSUAL HIGHLY STEREOSPECIFIC HANTZSCH-LIKE CYCLIZATION: FIRST AUTHENTICATED EXAMPLE OF 2-CHLOROMETHYLENE-1,2,3,4-TETRAHYDROPYRIDINE

Hantzsch cyclization of ethyl 4-chloro-2-benzylidene-acetoacetates 5 with methyl 3-aminocrotonate 6 leads to 2-chloromethylene-1,2,3,4-tetrahydropyridine-3,5-dicarboxylic esters 7.X-ray structure analysis and 1H-NMR of 7a established the configuration at